Among female malignant tumors, breast cancer consistently ranks first in incidence, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer accounting for about 70%. Treatment for these patients primarily relies on endocrine therapy, but advanced patients are prone to developing resistance, leading to treatment bottlenecks. The emergence of...
English
Arabic
French
Spanish
Portuguese
Deutsch
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek